Risk index score for bacteremia in febrile neutropenic episodes in children with malignancies

Journal of B.U.ON.

Volumn 14, Issue 3, 2009, Pages 411-418

  Spasova, Mariya Ivanova ^a   Grudeva Popova, J G ^a   Kostyanev, S S ^a   Genev, E D ^a   Stoyanova, A A ^a   Kirina, V I ^a   Moumdjiev, I N ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Bacteremia; Children; Febrile neutropenia; Malignancies; Risk stratification

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CANCER CHEMOTHERAPY; CELLULITIS; CENTRAL VENOUS CATHETER; CHILD; CHILL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; HUMAN; INFANT; INFECTION RISK; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIANAL CELLULITIS; PRESCHOOL CHILD; SCHOOL CHILD; SOLID TUMOR;

EID: 70350050231     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-2568.
2. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311. (Pubitemid 29350300)
3. Hann I, Viscoli C, Paesmans M et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580-588.
4. Kern WV, Cometta A, deBock R et al, for the International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-318.
5. Ammann RA, Simon A, De Bont E. Low-risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 2005; 44: 1-4.
6. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751. (Pubitemid 34194843)
7. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-1019.
8. Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149-158.
9. Newman J, Thompson C, Hussain Z, Bombassaro AM. Empiric antibiotic prescribing practice in febrile neutropenia: compliance with IDSA guidelines. Can J Hosp Pharm 2001; 54: 255-263. (Pubitemid 33094819)
10. Lehrnbecher T, Stanescu A, Kuhl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002; 30: 17-21. (Pubitemid 34146407)
11. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol 2003; 82 (Suppl 2): S105-S117.
12. Heney D, Lewis IJ, Evans SW et al. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992; 165: 886-890.
13. Raad II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization. Cancer 2003; 98: 1039-1047.
14. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 2002; 10: 189-196.
15. Jugo J, Crowe MJ, McClurg RB et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 2002; 50: 48-55. (Pubitemid 37554681)
16. Viscoli C, Bruzzi P, Castagnola E et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994; 30A: 430-437.
17. Santolaya ME, Villarroel M, Avendano LF, Cofre J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 1997; 25: 92-97. (Pubitemid 27293081)
18. Castagnola E, Paola D, Giacchino R, Viscoli C. Clinical and laboratory features predicting a favourable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: a literature review. J Hematother Stem Cell Res 2000; 9: 645-649. (Pubitemid 30848399)
19. Santolaya ME, Alvarez AM, Becker A et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19: 3415-3421. (Pubitemid 32642195)
20. Wilbur DW, Rentschler RE, Couperas JJ et al. Identifying neutropenic febrile cancer patients at risk for early death. Infect Med 2000; 17: 347-354.
21. Ammann RA, Hirt A, Luthy AR, Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003; 41: 436-443. (Pubitemid 37229435)
22. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41 (Suppl D): 65-80. (Pubitemid 28284508)
23. Lucas KG, Brown AE, Armstrong D et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-798. (Pubitemid 26055407)
24. Ammann RA, Hirt A, Luthy AR, Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis 2004; 23: 61-67. (Pubitemid 38176764)
25. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377-382.
26. Rackoff WR, Gonin R, Robinson C et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-924. (Pubitemid 26085537)
27. Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents 2000; 16: 93-95.
28. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994; 18: 589-595. (Pubitemid 24106912)
29. Engervall P, Granstrom M, Andersson B, Bjorkholm M. Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. Eur J Haematol 1995; 54: 226-234.
30. Lehrnbecher T, Venzon D, de Haas M et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999; 29: 414-419. (Pubitemid 29380209)
31. Ortega M, Rovira M, Almela M et al. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 2004; 33: 741-744. (Pubitemid 38499929)
32. Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis 1995; 21: 114-121.
33. Baorto EP, Aquino VM, Mullen CA et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001; 92: 909-913.
34. Madsen K, Rosenman M, Hui S, Breitfeld PP. Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol 2002; 24: 256-262. (Pubitemid 34506611)
35. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24: 38-42.
36. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 2000; 16: 107-111.